Head to head
Bristol-Myers Squibb vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: BMY · LLY
BMY
Bristol-Myers Squibb
61.27-1.57%
1-year price shape — +45% over the period
Quant Rating B · 71/100
vs
LLY
Eli Lilly and Co
1,154.76-1.31%
1-year price shape — +57% over the period
Quant Rating B · 77/100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (77); Eli Lilly and Co has done best over the past year (+57%); Eli Lilly and Co earns the most per share.
| BMY | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - General | Drug Manufacturers - General |
| Last price | 61.27 | 1,154.76 |
| Change today | -1.57% | -1.31% |
| 1-year return | +44.5% | +57.0% |
| Market cap | $125.16B | $1.09T |
| 52-week range | 41.13 – 68.64 | 711.59 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 13.50 | 38.76 |
| P/E percentile, own 5-yr range | 38th | 5th |
| P/B | 5.61 | 32.09 |
| Dividend yield | 4.10% | 0.56% |
| Profitability & growth | ||
| EPS (TTM) | 3.46 | 22.95 |
| Net profit (TTM) | $7.07B | $21.60B |
| Revenue (TTM) | $49.19B | $79.67B |
| Revenue growth (YoY) | +5.7% | +47.7% |
| Gross margin | 70.2% | 83.4% |
| Operating margin | 28.1% | 49.7% |
| Net margin | 18.9% | 33.5% |
| Free cash flow (TTM) | $11.44B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 83.2% | 79.5% |
| Insider activity (12mo) | 6 buy / 7 sell | 5 buy / 7 sell |
| Short interest (% of float) | 2.2% | 0.8% |
| Analyst consensus | 44% buy / 50% hold / 6% sell (18) | 86% buy / 10% hold / 5% sell (21) |
| Analyst price target | $68 (+11%) | $1,373 (+19%) |
| StockVane view | ||
| StockVane Quant Rating | B (71) | B (77) |
| Company | ||
| Employees | 32,500 | 50,000 |
| Founded | 1933 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.